Matrix metalloproteinase-2 polymorphisms and clinical outcome of Chinese patients with nonsmall cell lung cancer treated with first-line, platinum-based chemotherapy.
about
Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.RICTOR polymorphisms affect efficiency of platinum-based chemotherapy in Chinese non-small-cell lung cancer patients.The roles of beta-adrenergic receptors in tumorigenesis and the possible use of beta-adrenergic blockers for cancer treatment: possible genetic and cell-signaling mechanismsGSTP1 c.313A>G, XPD c.934G>A, XPF c.2505T>C and CASP9 c.-1339A>G Polymorphisms and Severity of Vomiting in Head and Neck Cancer Patients treated with Cisplatin Chemoradiation.Pharmacogenomics of platinum-based chemotherapy sensitivity in NSCLC: toward precision medicine.Polymorphisms in matrix metalloproteinases 2, 3, and 8 increase recurrence and mortality risk by regulating enzyme activity in gastric adenocarcinoma.
P2860
Matrix metalloproteinase-2 polymorphisms and clinical outcome of Chinese patients with nonsmall cell lung cancer treated with first-line, platinum-based chemotherapy.
description
2011 nî lūn-bûn
@nan
2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Matrix metalloproteinase-2 pol ...... , platinum-based chemotherapy.
@ast
Matrix metalloproteinase-2 pol ...... , platinum-based chemotherapy.
@en
type
label
Matrix metalloproteinase-2 pol ...... , platinum-based chemotherapy.
@ast
Matrix metalloproteinase-2 pol ...... , platinum-based chemotherapy.
@en
prefLabel
Matrix metalloproteinase-2 pol ...... , platinum-based chemotherapy.
@ast
Matrix metalloproteinase-2 pol ...... , platinum-based chemotherapy.
@en
P2093
P2860
P356
P1433
P1476
Matrix metalloproteinase-2 pol ...... , platinum-based chemotherapy.
@en
P2093
Baohui Han
Chunxue Bai
David H Garfield
Haijian Wang
Jiucun Wang
P2860
P304
P356
10.1002/CNCR.26669
P407
P577
2011-11-09T00:00:00Z